Shares of Orgenesis Inc. (NASDAQ:ORGS – Free Report) are set to reverse split before the market opens on Wednesday, September 25th. The 1-10 reverse split was announced on Monday, September 23rd. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, September 24th.
Orgenesis Stock Down 24.6 %
NASDAQ:ORGS traded down $0.13 during mid-day trading on Monday, hitting $0.39. 761,797 shares of the company’s stock were exchanged, compared to its average volume of 180,954. Orgenesis has a fifty-two week low of $0.25 and a fifty-two week high of $1.08. The company has a 50 day simple moving average of $0.70 and a 200-day simple moving average of $0.63.
Orgenesis (NASDAQ:ORGS – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share (EPS) for the quarter. The firm had revenue of $0.25 million for the quarter.
About Orgenesis
Orgenesis Inc, a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.
Further Reading
- Five stocks we like better than Orgenesis
- Most active stocks: Dollar volume vs share volume
- The Average 401k Balance by Age Explained
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- 3 REITs to Buy and Hold for the Long Term
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
